|
16 Sep 2020 |
Novus Therapeutics Announces Acquisition of Anelixis Therapeutics
|
|
16 Sep 2020 |
Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome
|
|
14 Sep 2020 |
RECOVERY COVID-19 Phase 3 Trial to Evaluate Regeneron's REGN-COV2 Investigational Antibody Cocktail in the UK
|
|
14 Sep 2020 |
PharmAbcine Unveils Olinvacimab's Positive Results from Phase Ib Combination Studies at KSMO 2020
|
|
14 Sep 2020 |
Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer
|
|
14 Sep 2020 |
Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis
|
|
14 Sep 2020 |
HiFiBiO Therapeutics Announces a Global Strategic Partnership With ABL Bio for the Co-Development of a SARS-CoV-2 Neutralizing Antibody
|
|
14 Sep 2020 |
FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis
|
|
14 Sep 2020 |
Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)
|
|
12 Sep 2020 |
Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
|
|
12 Sep 2020 |
Celltrion Announces Positive Interim Results From Phase I Trial of CT-P59, an Anti-COVID-19 Monoclonal Antibody Treatment Candidate
|
|
11 Sep 2020 |
Fasenra met both co-primary endpoints of reduced nasal polyp size and blockage in the OSTRO Phase III trial for patients with chronic rhinosinusitis with nasal polyps
|
|
11 Sep 2020 |
Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
|
|
10 Sep 2020 |
Totient Partners with Ginkgo Bioworks to Apply Unique Discovery Platform to COVID-19 Antibody Efforts
|
|
10 Sep 2020 |
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
|
|
10 Sep 2020 |
Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Light Chain (AL) Amyloidosis
|
|
10 Sep 2020 |
Avillion announces positive top-line results of Phase 2 trial of sonelokinab (M1095), an anti-IL-17 A/F Nanobody®, in chronic psoriasis
|
|
10 Sep 2020 |
Trillium Therapeutics Announces Updated Data From Its Ongoing TTI-622 and TTI-621 Dose Escalation Studies
|
|
09 Sep 2020 |
Alligator Bioscience presents an update regarding the Phase I study with the drug candidate ATOR-1015
|
|
08 Sep 2020 |
Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody
|
|
08 Sep 2020 |
AVEO Oncology Regains Full Global Rights to Ficlatuzumab
|
|
07 Sep 2020 |
IcanoMAB GmbH Founded with Private Funding to Develop Precision Canonical Monoclonal Antibodies in Oncology, Immune-Modulation, Acute Inflammation and Most Urgently for Covid-19
|
|
05 Sep 2020 |
AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
|
|
04 Sep 2020 |
Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara® (Ustekinumab)
|
|
04 Sep 2020 |
Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study
|
